Bavarian Nordic Secures $160M to Accelerate Life-Saving Vaccine Innovations

Bavarian Nordic is excited to announce that we have successfully raised $160,000,000 to drive our mission of improving and saving lives through innovative vaccines. With over 25 years of expertise in developing life-saving vaccines, our fully integrated company has become a trusted global leader in smallpox and mpox vaccines, crafted through our long-standing partnership with the U.S. Government. This funding will significantly bolster our development, manufacturing, and commercialization efforts, enabling us to advance our comprehensive portfolio of vaccines that serve travelers, address endemic diseases, and enhance public health preparedness worldwide. As pioneers in the vaccine industry, our investment in cutting-edge research and development is a steadfast reflection of our commitment to innovation and excellence. The new capital will accelerate our mission-critical projects and expand our capabilities to meet emerging infectious disease challenges, ensuring our vaccines are accessible to communities across the globe. At Bavarian Nordic, our DNA is defined by persistence, adaptability, and compassion, values that guide every initiative and decision. Our diverse global team of over 1,400 dedicated professionals works collaboratively in a dynamic, inclusive environment where personal and professional growth are paramount. As we navigate an ever-changing world of health challenges, this infusion of capital not only amplifies our potential to safeguard lives daily but also reinforces our strategic vision for the future. We invite like-minded partners, investors, and talent to join us in our journey, as together, we harness the power of innovation to create a healthier, safer future for all.